Biocon Biologics, a subsidiary of Biocon, focuses on the Group’s biosimilars business. It has one of the largest global biosimilars portfolios spanning recombinant human insulin (rh-Insulin), insulin analogs, monoclonal antibodies and other biologics for oncology, immunology and other therapeutic areas. The company is well positioned to offer lowered costs and more access to this highly innovative class of drugs. The demand for biosimilars is set to grow as patents expire on leading biologics and pressure for lower priced drugs increases.
Through Biocon Sdn Bhd, Biocon has set up Asia’s largest integrated insulin manufacturing and Research and Development (R&D) facility in Malaysia with an investment of USD325 million. This also positions it as the largest foreign investment in biotechnology in Malaysia. More importantly, this reflects Biocon’s commitment to put affordable life-changing medicines within the reach of patients across the world.
Commercial operations commenced in 2016 with Biocon’s recombinant human insulin to be the first locally manufactured biosimilar product approved for sale in Malaysia. The facility also provides an opportunity to export affordable insulin therapies to other global regions.
With Asia’s largest integrated insulin manufacturing and R&D facility, Biocon brings many significant advantages to healthcare in Malaysia through a strategic partnership with Duopharma Biotech Berhad, Malaysia’s leading pharmaceutical company. The partnership is leveraging its innovation capabilities and ingenuity to open up a world of possibilities for healthcare professionals and patients. Patient outcomes are improving with affordable cancer and insulin therapies. Biocon Sdn Bhd and Duopharma Marketing Sdn Bhd boosted the supply of locally produced Insugen (recombinant human insulin). The successful launch of Basalog One (Insulin Glargine pen) as well as Zuhera (Trastuzumab) replaced the fear of disease with the hope of a better life for Malaysians.
Source: MIDA e-Newsletter August 2021